Harrow Inc. (HROW)
NASDAQ (NMS) NASDAQ (NMS) Primary Summary
Harrow: Vevye Replaces Xiidra On Tier 1 Formulary At CVS
Harrow, Inc. is experiencing explosive growth, driven by its success in branded pharmaceuticals, especially Vevye. Vevye, HROW's flagship dry eye drug, is projected to reach $100M in 2025 and $300M in 2026, with potential for $2B+ by 2030. HROW's financials are accelerating: FCF/share expected at $4 in 2026 and $10 in 2027, with leverage rapidly declining and EBITDA margins rising.
Harrow Q3 Earnings Preview: This Business Has Eye-Popping Potential
Harrow, Inc. is an ophthalmology company with strong revenue growth, ambitious targets, and a diverse product portfolio including Vevye and Iheezo. HROW targets $280M in 2025 revenue and >$250M per quarter by Q4 2027, leveraging recent acquisitions and biosimilar partnerships. Despite low profitability and modest cash reserves, HROW's experienced management, robust pipeline, and expanding market share support a bullish long-term outlook.
Harrow: Positive And Negative Adjustments After Investor Day Offset Each Other
Harrow's recent debt refinancing, Melt Pharmaceuticals acquisition plans, and updated peak sales estimates reinforce the bullish thesis. Base case DCF modeling projects significant revenue growth through 2034, with relatively conservative assumptions on margins and product adoption. I reiterate a "Buy" rating for HROW stock, with ~88% upside to a $72.7 base case fair value, including some risk adjustments.
Harrow Inc. (HROW) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Harrow Inc. ever had a stock split?
Harrow Inc. Profile
| Specialty Retail Industry | Consumer Discretionary Sector | Mark L. Baum CEO | NASDAQ (NMS) Exchange | 415858109 CUSIP |
| US Country | 382 Employees | - Last Dividend | 8 Feb 2013 Last Split | 28 Sep 2007 IPO Date |
Overview
Harrow, Inc. is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of a wide range of ophthalmic pharmaceutical products. Initially founded in 1998 and headquartered in Nashville, Tennessee, the company has a strong focus on addressing the diverse needs within the field of ophthalmology. Its portfolio spans from compounded medications designed for specific patient needs to advanced therapeutic solutions for common and complex eye conditions. Originally known as Harrow Health, Inc., it underwent a name change to Harrow, Inc. in September 2023, reflecting its evolved position and broadened scope in the eyecare pharmaceutical landscape.
Products and Services
- ImprimisRx - A line of ophthalmology-focused compounded medications designed to meet specific patient needs in eye care.
- IHEEZO - Chloroprocaine hydrochloride ophthalmic gel, offering anesthesia for eye procedures.
- Ophthalmic Solutions - Includes products like IOPIDINE, VEVYE, and ZERVIATE, catering to various ophthalmic needs.
- MAXITROL Eye Drops - Provides treatment for bacterial infections, inflammation, and redness in the eyes.
- ILEVRO and NEVANAC - Non-steroidal and anti-inflammatory eye drops for managing pain and inflammation post-cataract surgery.
- VIGAMOX - A fluoroquinolone antibiotic eye drop for treating bacterial conjunctivitis.
- MAXIDEX and FLAREX - Steroid eye drops used for treating various steroid-responsive inflammatory conditions of the eye.
- TRIESENCE - A steroid injection aimed at treating ophthalmic diseases and aiding in visualization during vitrectomy procedures.
- NATACYN - An antifungal drug in sterile form for treating fungal infections of the eye like blepharitis, conjunctivitis, and keratitis.
- TOBRADEX ST - A combined tobramycin and dexamethasone ophthalmic suspension for bacterial infections and inflammation of the eye.
- VERKAZIA - Cyclosporine ophthalmic emulsion used for treating chronic, severe keratitis.
- FRESHKOTE Preservative Free (PF) - A lubricant eye drop designed to relieve dry eye symptoms without the use of preservatives.
Contact Information
